Business Context and Reporting Period
Pavmed Inc. (PAVM) filed a Form 8-K on April 17, 2025, reporting the entry into a material definitive agreement. The company is incorporated in Delaware and maintains its principal executive offices in New York, New York.
Key Financial Metrics and Transaction Details
This filing does not report revenue, profit, cash flow, or historical financial performance. The primary financial metric disclosed relates to a new capital raising facility:
- Maximum Offering Amount: $2,880,000 in shares of common stock.
- Commission Fee: 3.0% of aggregate gross sales prices paid to the sales agent.
- Legal Fee Cap (Execution): Up to $50,000.
- Legal Fee Cap (Quarterly): Up to $5,000 per calendar quarter for representation dates.
Material Changes
The material change reported is the execution of a Sales Agreement with Maxim Group LLC on April 17, 2025. This agreement establishes an "at-the-market" (ATM) offering program allowing the company to sell shares from time to time. The offering is conducted pursuant to an effective shelf registration statement (Form S-3) declared effective on April 15, 2025.
Guidance, Outlook, and Risks
Use of Proceeds: The company intends to use net proceeds for working capital and general corporate purposes.
Termination Rights: The agreement may be terminated by either party with ten business days' written notice, or immediately by the agent under certain circumstances.
Risks: The filing includes standard disclaimers that the agreement is not an offer to sell securities in jurisdictions where such an offer would be unlawful without registration. The text notes that representations and warranties are for the allocation of risk between parties and may be subject to limitations.
Investor Verification Checklist
- Verify the current number of authorized but unissued shares to ensure the $2,880,000 cap does not exceed available authorization.
- Review the effective shelf registration statement (File No. 333-283994) for any additional restrictions on the offering.
- Monitor future filings for actual sales volumes and proceeds generated under the ATM program.
- Confirm the company's current cash position to assess the immediate necessity of the working capital raise.